InsidersTradesSigma
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
Browse the full record of transactions filed by Ainsworth Sean. Insider active across 2 companies, notably Opus Genetics, Inc.. In total, 7 reports have been logged. History available since 19 October 2022. The latest transaction was filed on 20 April 2026 (Attribution). Regulator: SEC (Form 4). The full history is free.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
7 条申报中的 7 条
Ainsworth Sean is a declarant, with 7 filings in total. Across the 7 sampled recent filings, both buy and sell amounts are 0 EUR, the most common transaction nature is Attribution, and the period runs from 2022-10-20 to 2026-04-22. He is a Director at Opus Genetics, Inc. and Ocuphire Pharma, Inc.; among the top filings are 86,069.48662319977 EUR at Opus Genetics, Inc. on 2025-08-27, and 0.1638256112637568 EUR at Ocuphire Pharma, Inc. on 2022-10-20.